**S3 Table. Baseline characteristics telaprevir and boceprevir treated patients**

|  |  |  |  |
| --- | --- | --- | --- |
| Characteristic  | Telaprevir (n=265) | Boceprevir (n=202) | p-value(TPR/BOC) |
| Age, y – mean (range) | 51 (19-71) | 51 (22-77) | 0.84 |
| Male sex – n (%)  | 174 (66) | 145 (72) | 0.16 |
| White race – n (%)a | 186 (89) | 135 (90) | 0.43 |
| HCV genotype – n (%)  Genotype 1 indeterminate  Genotype 1a  Genotype 1b | 31 (20)121 (46)91 (34) | 33 (16)105 (52)64 (32) | 0.35 |
| Previous responseb   Naive  Relapse  Nonresponse  Viral breakthrough  Early discontinuation | 152 (59)40 (15)47 (18)11 (4)7 (3) | 121 (61)36 (18)31 (16)5 (3)4 (2) | 0.70 |
| Decompensated liver disease – n (%) | 12 (5) | 12 (6) | 0.49 |
| Metavir score F3-4c  | 96 (52) | 65 (52) | 0.97 |
| Laboratory valuesd |  |  |  |
| Haemoglobin g/dl - mean (SD) | 9.1 (0.9) | 9.2 (0.9) | 0.29 |
| Leucocyte count x109/L - mean (SD) | 6.8 (2.1) | 6.7 (2.2) | 0.74 |
| Neutrophil count x109/L - mean (SD) | 3.5 (1.6) | 3.4 (1.5) | 0.66 |
| Platelet count x109/L – mean (range) | 195 (51 – 764) | 188 (24-387) | 0.31 |
| Albumin g/l – mean (range)  | 41.8 (24-51) | 40.9 (24-49) | 0.06 |
| Total bilirubin g/dl – median (IQR) | 10 (7-14) | 9.9 (7-14) | 0.82 |

a Race: available in 360 patients; b Previous response: available in 454 patients (257 TPR, 197 BOC); cMetavir score: available in 308 patients (184 TPR, 124 BOC); dLab values >10% missings in: neutrophil count, albumin;